Un mecanismo dependiente de los eosinófilos para el efecto antitumoral de la interleucina-4
R I Tepper1, R L Coffman, P Leder
1MGH Cancer Center, Massachusetts General Hospital, Charlestown 02129.
Science (New York, N.Y.)
|July 24, 1992
Resumen
La interleucina-4 murina (IL-4) demuestra efectos antitumorales significativos mediante el reclutamiento de eosinófilos en los sitios del tumor. Esta investigación sugiere la matanza de tumores mediada por IL-4 como una posible terapia contra el cáncer.
Área de la Ciencia:
- Inmunología Inmunología.
- Oncología Oncología.
Sus antecedentes:
- La interleucina-4 murina (IL-4) muestra actividad antitumoral en el sitio del tumor.
- La muerte de las células tumorales inducida por IL-4 involucra a los eosinófilos y macrófagos, con una presencia mínima de linfocitos.
Objetivo del estudio:
- Para identificar el tipo específico de célula responsable de la acción antitumoral de la IL-4.
- Para investigar el papel de los eosinófilos en la citotoxicidad tumoral mediada por IL-4.
Principales métodos:
- Administración in vivo de anticuerpos que bloquean la acumulación de granulocitos.
- Análisis de la regresión tumoral en cepas de ratón mutante con deficiencia de linfocitos.
Principales resultados:
- Los eosinófilos están implicados como las células efectoras primarias en la citotoxicidad tumoral mediada por IL-4.
- El efecto antitumoral de la IL-4 es independiente de los linfocitos.
Conclusiones:
- La administración localizada de IL-4 puede inducir la regresión de los tumores establecidos.
- La matanza de tumores mediada por IL-4 presenta una estrategia terapéutica prometedora para los cánceres humanos.
Videos de Conceptos Relacionados
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...